PDL BIOPHARMA, INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Private
- Established
- 1986-01-01
- Employees
- 251
- Market Cap
- -
- Website
- http://www.pdl.com
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
Terminated
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2006-07-25
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00355901
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
Phase 2
Terminated
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2006-01-24
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00281294
- Locations
- ๐บ๐ธ
The Center for Rheumatology, Albany, New York, United States
๐บ๐ธDenver Arthritis Clinic, Denver, Colorado, United States
๐บ๐ธJustus J. Fiechtner MD PC, Lansing, Michigan, United States
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Phase 2
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2005-04-25
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT00109161
- Locations
- ๐บ๐ธ
University of Cincinnati, Cincinnati, Ohio, United States
๐บ๐ธMayo Clinic, Scottsdale, Arizona, United States
๐บ๐ธUniversity of Rochester Medical Center, Rochester, New York, United States
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
Phase 2
Completed
- Conditions
- MelanomaMetastases
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2008-08-05
- Lead Sponsor
- PDL BioPharma, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00099970
- Locations
- ๐บ๐ธ
Cancer Institute Medical Group, Inc., Santa Monica, California, United States
๐บ๐ธUCLA School of Medicine, Los Angeles, California, United States
๐บ๐ธArizona Cancer Center, Tucson, Arizona, United States
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2
- Conditions
- Lymphoma
- First Posted Date
- 2003-06-10
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- PDL BioPharma, Inc.
- Registration Number
- NCT00014664
- Locations
- ๐บ๐ธ
Protein Design Labs, Inc., Freemont, California, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath